Increased bone mass in adult prostacyclin-deficient mice

Journal of Endocrinology

Volumn 204, Issue 2, 2010, Pages 125-133

  Nakalekha, Chalida ^a   Yokoyama, Chieko ^a,b   Miura, Hiroyuki ^a   Alles, Neil ^a   Aoki, Kazuhiro ^a   Ohya, Keiichi ^a   Morita, Ikuo ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN E2 SYNTHASE; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT ANIMAL; AGING; ANIMAL EXPERIMENT; ARTICLE; BONE MASS; BONE METABOLISM; BONE TISSUE; BONE TURNOVER; CONTROLLED STUDY; FEMALE; KNOCKOUT MOUSE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PARAMETER; PRIORITY JOURNAL; TRABECULAR BONE; WILD TYPE;

AGING; ANIMALS; BONE AND BONES; CALCIFICATION, PHYSIOLOGIC; CYTOCHROME P-450 ENZYME SYSTEM; EPOPROSTENOL; FEMALE; HYBRIDIZATION, GENETIC; INTRAMOLECULAR OXIDOREDUCTASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOGENESIS; PHENOTYPE;

EID: 75149125762     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-09-0376     Document Type: Article

References (39)

1. Alles N, Soysa NS, Hussain MD, Tomomatsu N, Saito H, Baron R, Morimoto N, Aoki K, Akiyoshi K & Ohya K 2009 Polysaccharide nanogel delivery of a TNF-alpha and RANKL antagonist peptide allows systemic prevention of bone loss. European Journal of Pharmaceutical Sciences 37 83-88.
2. Aoki K, Saito H, Itzstein C, Ishiguro M, Shibata T, Blanque R, Mian AH, Takahashi M, Suzuki Y, Yoshimatsu M et al. 2006 A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. Journal of Clinical Investigation 116 1525-1534.
3. Arikawa T, Omura K & Morita I 2004 Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. Journal of Cellular Physiology 200 400-406.
4. Clarkin CE, Emery RJ, Pitsillides AA & Wheeler-Jones CP 2008 Evaluation of VEGF-mediated signaling in primary human cells reveals a paracrine action for VEGF in osteoblast-mediated crosstalk to endothelial cells. Journal of Cellular Physiology 214 537-544.
5. Deckers MM, Karperien M, van der Bent C, Yamashita T, Papapoulos SE & Lowik CW 2000 Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 141 1667-1674.
6. Gao Q, Zhan P, Alander CB, Kream BE, Hao C, Breyer MD, Pilbeam CC & Raisz LG 2009 Effects of global or targeted deletion of the EP4 receptor on the response of osteoblasts to prostaglandin in vitro and on bone histomorphometry in aged mice. Bone 45 98-103.
7. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT & Delaisse JM 2003 The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. Journal of Bone and Mineral Research 18 859-867.
8. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK & DuBois RN 2000 Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. PNAS 97 13275-13280.
9. Hagino H, Kuraoka M, Kameyama Y, Okano T & Teshima R 2005 Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading. Bone 36 444-453.
10. Harada S & Rodan GA 2003 Control of osteoblast function and regulation of bone mass. Nature 423 349-355.
11. Hatae T, Wada M, Yokoyama C, Shimonishi M & Tanabe T 2001 Prostacyclin-dependent apoptosis mediated by PPAR delta. Journal of Biological Chemistry 276 46260-46267.
12. Hertz R, Berman I, Keppler D & Bar-Tana J 1996 Activation of gene transcription by prostacyclin analogues is mediated by the peroxisomeproliferators-activated receptor (PPAR). European Journal of Biochemistry 235 242-247.
13. Hussain Mian A, Saito H, Alles N, Shimokawa H, Aoki K & Ohya K 2008 Lipopolysaccharide-induced bone resorption is increased in TNF type 2 receptor-deficient mice in vivo. Journal of Bone and Mineral Metabolism 26 469-477.
14. Ito M, Nakayama K, Konaka A, Sakata K, Ikeda K & Maruyama T 2006 Effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate on trabecular microstructure and bone strength in mature ovariectomized rats. Bone 39 453-459.
15. Kamei D, Yamakawa K, Takegoshi Y, Mikami-Nakanishi M, Nakatani Y, Oh-Ishi S, Yasui H, Azuma Y, Hirasawa N, Ohuchi K et al. 2004 Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1. Journal of Biological Chemistry 279 33684-33695.
16. Kato N, Kitahara K, Rittling SR, Nakashima K, Denhardt DT, Kurosawa H, Ezura Y & Noda M 2007 Osteopontin deficiency enhances anabolic action of EP4 agonist at a sub-optimal dose in bone. Journal of Endocrinology 193 171-182.
17. Li X, Okada Y, Pilbeam CC, Lorenzo JA, Kennedy CR, Breyer RM & Raisz LG 2000 Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology 141 2054-2061.
18. Li M, Healy DR, Li Y, Simmons HA, Crawford DT, Ke HZ, Pan LC, Brown TA & Thompson DD 2005 Osteopenia and impaired fracture healing in aged EP4 receptor knockout mice. Bone 37 46-54.
19. Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, Morrow JD, DuBois RN, Trzaskos JM & Dey SK 1999 Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes and Development 13 1561-1574.
20. Miyaura C, Inada M, Suzawa T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S & Suda T 2000 Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. Journal of Biological Chemistry 275 19819-19823.
21. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N et al. 1997 Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 678-682.
22. Naik AA, Xie C, Zuscik MJ, Kingsley P, Schwarz EM, Awad H, Guldberg R, Drissi H, Puzas JE, Boyce B et al. 2009 Reduced COX-2 expression in aged mice is associated with impaired fracture healing. Journal of Bone and Mineral Research 24 251-264.
23. Namba T, Oida H, Sugimoto Y, Kakizuka A, Negishi M, Ichikawa A & Narumiya S 1994 cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. Journal of Biological Chemistry 269 9986-9992.
24. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM & Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. Journal of Bone and Mineral Research 2 595-610.
25. Raisz LG 1995 Physiologic and pathologic roles of prostaglandins and other eicosanoids in bone metabolism. Journal of Nutrition 125 2024S-2027S.
26. Raisz LG 1999 Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis and Cartilage 7 419-421.
27. Raisz LG & Fall PM 1990 Biphasic effects of prostaglandin E2 on bone formation in cultured fetal rat calvariae: interaction with cortisol. Endocrinology 126 1654-1659.
28. Rawlinson SC, el-Haj AJ, Minter SL, Tavares IA, Bennett A & Lanyon LE 1991 Loading-related increases in prostaglandin production in cores of adult canine cancellous bone in vitro: a role for prostacyclin in adaptive bone remodeling? Journal of Bone and Mineral Research 6 1345-1351.
29. Rawlinson SC, Wheeler-Jones CP & Lanyon LE 2000 Arachidonic acid for loading induced prostacyclin and prostaglandin E(2) release from osteoblasts and osteocytes is derived from the activities of different forms of phospholipase A(2). Bone 27 241-247.
30. Saito H, Kojima T, Takahashi M, Horne WC, Baron R, Amagasa T, Ohya K & Aoki K 2007 A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis. Arthritis and Rheumatism 56 1164-1174.
31. Simmons DL, Botting RM & Hla T 2004 Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacological Reviews 56 387-437.
32. Stitham J, Arehart EJ, Gleim SR, Douville KL & Hwa J 2007 Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. Prostaglandins & Other Lipid Mediators 82 95-108.
33. Sugimoto Y & Narumiya S 2007 Prostaglandin E receptors. Journal of Biological Chemistry 282 11613-11617.
34. Tomomatsu N, Aoki K, Alles N, Soysa NS, Hussain A, Nakachi H, Kita S, Shimokawa H, Ohya K & Amagasa T 2009 LPS-induced inhibition of osteogenesis is TNF-alpha dependent in a murine tooth extraction model. Journal of Bone and Mineral Research 24 1770-1781.
35. Tuncbilek G, Korkusuz P & Ozgur F 2008 Effects of iloprost on calvarial sutures. Journal of Craniofacial Surgery 19 1472-1480.
36. Uematsu S, Matsumoto M, Takeda K & Akira S 2002 Lipopolysaccharide- dependent prostaglandin E(2) production is regulated by the glutathione- dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. Journal of Immunology 168 5811-5816.
37. Yokoyama C, Yabuki T, Shimonishi M, Wada M, Hatae T, Ohkawara S, Takeda J, Kinoshita T, Okabe M & Tanabe T 2002 Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 106 2397-2403.
38. Yoshida K, Oida H, Kobayashi T, Maruyama T, Tanaka M, Katayama T, Yamaguchi K, Segi E, Tsuboyama T, Matsushita M et al. 2002 Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. PNAS 99 4580-4585.
39. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN & O'Keefe RJ 2002 Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. Journal of Clinical Investigation 109 1405-1415.